Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody

Tanushree Dangi, Sarah Sanchez, Jacob Class, Michelle Richner, Lavanya Visvabharathy, Young Rock Chung, Kirsten Bentley, Richard J. Stanton, Igor J. Koralnik, Justin M. Richner*, Pablo Penaloza-MacMaster*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal antibody (mAb) therapies. Immune responses to other viral antigens are generated after SARS-CoV-2 infection, but their contribution to the antiviral response remains unclear. Here, we interrogated whether nucleocapsid-specific antibodies can improve protection against SARS-CoV-2. We first immunized mice with a nucleocapsid-based vaccine and then transferred sera from these mice into naive mice, followed by challenge with SARS-CoV-2. We show that mice that received nucleocapsid-specific sera or a nucleocapsid-specific mAb exhibited enhanced control of SARS-CoV-2. Nucleocapsid-specific antibodies elicited NK-mediated, antibody-dependent cellular cytotoxicity (ADCC) against infected cells. To our knowledge, these findings provide the first demonstration in the coronavirus literature that antibody responses specific to the nucleocapsid protein can improve viral clearance, providing a rationale for the clinical evaluation of nucleocapsid-based mAb therapies to treat COVID-19.

Original languageEnglish (US)
Article numbere162282
JournalJournal of Clinical Investigation
Issue number23
StatePublished - Dec 1 2022

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody'. Together they form a unique fingerprint.

Cite this